A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L

West Japan Oncology Group

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel (CbP) showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of TC. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.

Original languageEnglish
Article numbermdu541
Pages (from-to)363-368
Number of pages6
JournalAnnals of Oncology
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Thymoma
Carboplatin
Paclitaxel
Drug Therapy
Anthracyclines
Non-Small Cell Lung Carcinoma
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma : WJOG4207L. / West Japan Oncology Group.

In: Annals of Oncology, Vol. 26, No. 2, mdu541, 01.02.2015, p. 363-368.

Research output: Contribution to journalArticle

@article{d03ad3fe449943deb99309c37da88978,
title = "A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L",
abstract = "In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel (CbP) showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of TC. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.",
author = "{West Japan Oncology Group} and F. Hirai and T. Yamanaka and K. Taguchi and H. Daga and A. Ono and K. Tanaka and Y. Kogure and Fumihiko Hirai and T. Kimura and J. Fukuoka and Y. Iwamoto and H. Sasaki and K. Takeda and Takashi Seto and Y. Ichinose and K. Nakagawa and Yoichi Nakanishi",
year = "2015",
month = "2",
day = "1",
doi = "10.1093/annonc/mdu541",
language = "English",
volume = "26",
pages = "363--368",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma

T2 - WJOG4207L

AU - West Japan Oncology Group

AU - Hirai, F.

AU - Yamanaka, T.

AU - Taguchi, K.

AU - Daga, H.

AU - Ono, A.

AU - Tanaka, K.

AU - Kogure, Y.

AU - Hirai, Fumihiko

AU - Kimura, T.

AU - Fukuoka, J.

AU - Iwamoto, Y.

AU - Sasaki, H.

AU - Takeda, K.

AU - Seto, Takashi

AU - Ichinose, Y.

AU - Nakagawa, K.

AU - Nakanishi, Yoichi

PY - 2015/2/1

Y1 - 2015/2/1

N2 - In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel (CbP) showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of TC. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.

AB - In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel (CbP) showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of TC. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.

UR - http://www.scopus.com/inward/record.url?scp=84925300119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925300119&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu541

DO - 10.1093/annonc/mdu541

M3 - Article

C2 - 25403584

AN - SCOPUS:84925300119

VL - 26

SP - 363

EP - 368

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

M1 - mdu541

ER -